Company News

This press release is posted as a service by Angioplasty.Org



Borgess Medical Center Enhances Cardiac Capabilities
for Advanced Patient Care

Heart Center Acquires Newest Diagnostic Imaging Technology from Toshiba

TUSTIN, March 28, 2006 – Improving the accessibility and delivery of cardiac care to the residents of Michigan, Toshiba America Medical Systems, Inc. (TAMS) today announced that Borgess Medical Center in Kalamazoo has installed five Infinix™-i series catheterization labs, the latest in diagnostic and interventional imaging technology. The labs are part of a suite of cardiac imaging systems, including Toshiba’s Aquilion™ CFX CT scanner, designed to reveal cardiovascular disease (CVD) at its earliest stages. CVD is the number one cause of death in Michigan and killed more than 31,000 people in 20031.

According to Tim Fischell, M.D., director of cardiac research at the Borgess Heart Center for Excellence, incorporating diagnostic imaging into the center’s practice has dramatically improved the level of cardiac care they are able to deliver to patients. “CVD continues to be a major problem in our communities, and advances in diagnostic imaging have had a significant impact in diagnosing disease of the heart at its earliest stages and preventing death.”

The center recently installed five flat panel based Infinix-i series catheterization labs, including three Infinix CC-i, designed to provide superior image quality at a low dose; an Infinix DP-i, for cardiac and peripheral work without compromise in one room; and an Infinix CB-i ideal for interventional procedures such as stent placement or angioplasty. The center also has plans to install an additional Infinix CC-i.

The newly installed cardiac catheterization labs, which serve the center’s electrophysiology, diagnostic and interventional catheterization needs, were designed to complement the center’s existing Aquilion 64-slice CT scanner, which can image the entire heart in less than five seconds.

Collectively, these diagnostic imaging technologies allow Borgess to meet its patients’ total cardiovascular needs and makes the medical center home to one of the largest grouping of Toshiba’s vascular imaging technology anywhere in the U.S.

About Borgess Health
The newly opened Borgess Heart Institute at Borgess Medical is one of the largest, and most advanced tertiary cardiac centers in western Michigan. The Center performs more than 7,000 cardiac procedures per year, and offers state-of-the art treatment for patients with coronary heart disease, CHF, peripheral vascular disease and cardiac arrhythmias. Borgess Health includes more than 120 sites of care in 15 southern Michigan cities, as well as eight owned or affiliated hospitals, a nursing home, ambulatory care facilities, home health care, physician practices, managed care services, a cancer center and an air ambulance service. These Health Alliance members form a health care network that offers a complete continuum of services to the 1.1 million people living in 11 counties in southwest and southcentral Michigan.

About Toshiba
With headquarters in Tustin, Calif., Toshiba America Medical Systems markets, sells, distributes and services diagnostic imaging systems, and coordinates clinical diagnostic imaging research for all modalities in the United States. Toshiba Medical Systems Corporation, an independent group company of Toshiba Corporation, is a global leading provider of diagnostic medical imaging systems and comprehensive medical solutions, such as CT, X-ray, Ultrasound, Nuclear Medicine, MRI and information systems. Toshiba Corporation is a leader in information and communications systems, electronic components, consumer products, and power systems. Toshiba has approximately 161,000 employees worldwide and annual sales of $53 billion.

Infinix and Aquilion are trademarks of Toshiba Medical Systems Corporation.

1. www.michigan.gov/documents/CVDFactsheet2005col_121221_7.pdf

Source: Toshiba America Medical Systems, Inc.

Angioplasty.Org Home •  PatientCenter

this press release is posted as a reader service by Angioplasty.org,
an editorially independent informational health site
which has received unrestricted educational grants from
Medtronic plc, TCROSS NEWS, Toshiba America Medical Systems, Volcano Corporation, Terumo Medical Corporation
Cardium Therapeutics, Inc. and Lenox Hill Heart and Vascular Institute of NY
All content, including text, photos and video
©Copyright Venture Digital LLC 1996-2021